Returning in September as a digital event, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD, dry AMD, DME, IRDs and more.
Discover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics, Biogen, Gyroscope Therapeutics, Novartis, Horama and REGENXBIO
Join 150+ fellow industry attendees from discovery, preclinical and clinical backgrounds, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders.
This meeting will allow you to:
- Hear the latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation
- Highlight optogenetics and gene agnostic approaches from SparingVision, GenSight Biologics and Bionic Sight
- Learn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures
- Discuss the clinical progress with different administration routes to the eye with clinical experience from REGENXBIO
- Gain key vector insights from Eyevensys, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing
- Explore the realities of clinical trial design to meet regulatory expectations throughout a program, with insights from Gensight Biologics
- Hear pharma representatives discuss the opportunities and realities of collaborating with biotechs, with experience from Novartis
- Hear from a Luxturna patient to understand their first-hand experience of receiving the therapy, and have an opportunity to ask them your questions
- Highlighting progress in ASOs for ophthalmic disorders for a deeper understanding of the ophthalmic landscape with data from ProQR
View the event guide here for full agenda details and the expert speaker faculty.